Prof. Christopher Chao, Vice President (Research and Innovation) of PolyU led an engaging panel session to discuss diverse industry issues , including medical and healthcare innovations, healthcare development and prospects for healthcare investment.
PolyU has signed a Memorandum of Understanding (MOU) with PanMediso, with the aim of advancing collaboration in the healthcare sector.
Prof. Larry Chow, Head and Professor of the Department of Applied Biology & Chemical Technology of PolyU, led a thematic session on "Innovative Drugs in Shaping China's Biopharma Ecosystem."
The two sessions demonstrated PolyU's commitment to advancing healthcare solutions and strengthening Hong Kong's position as a global hub for innovation and collaboration.
PolyU has actively participated in the ASGH 2024, showcasing a number of cutting-edge projects.
The Hong Kong Polytechnic University (PolyU) has actively participated in the Asia Summit on Global Health 2024, showcasing a number of cutting-edge projects and leading two thought-provoking discussions to share the university’s insights and leadership in fostering healthcare innovation and collaboration.
Prof. Christopher Chao, Vice President (Research and Innovation) of PolyU, joined more than 80 global healthcare leaders at the opening of ASGH and led an engaging panel session on "Fostering Collaboration for Next-Gen Healthcare Business.” The session aimed to discuss diverse industry issues, including medical and healthcare innovations, healthcare development and prospects for healthcare investment.
In addition, PolyU has signed a significant Memorandum of Understanding (MOU) with PanMediso, with the aim of advancing collaboration in the healthcare sector.
Furthermore, an academic-led startup nurtured and supported by PolyU has announced its leadership in the implementation of the five-year “LiverCare – Hong Kong 10 Million Liver Scans Program”, to improve public awareness of liver disease prevention.
On Day 2 of ASGH, PolyU hosted a thematic session titled "Innovative Drugs in Shaping China's Biopharma Ecosystem." The session was chaired by Prof. Larry Chow, Head and Professor of the Department of Applied Biology & Chemical Technology of PolyU, together with the participation of Prof. Zhao Yanxiang, Associate Head and Professor of the Applied Biology and Chemical Technology of PolyU, and other specialists from Shanghai Pharmaceuticals Holding Co., Ltd, AstraZeneca, and Simcere Pharmaceutical Group Ltd.
The panel discussed the evolving biopharma ecosystem in China, focusing on the role of innovative drugs and the collaborative efforts driving industry progress. They also addressed strategic initiatives essential for sustaining growth and competitiveness in the market.
The two sessions attracted a large and engaged audience, reflecting a strong interest in these critical topics and demonstrating PolyU's commitment to advancing healthcare solutions and strengthening Hong Kong's position as a global hub for innovation and collaboration.
The ASGH was jointly organised by the Government of the Hong Kong Special Administrative Region and the Hong Kong Trade Development Council.
